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1. Introduction 
Glycogen metabolism in skeletal muscle is con- 
trolled by a regulatory network which involves three 
protein kinases and two protein phosphatases (fig.1 
and ref. [l] for recent review). The conversion of 
phosphorylase b to a is catalysed by phosphorylase 
kinase while the activity of phosphorylase kinase is 
itself controlled by cyclic AMP-dependent protein 
kinase. This latter reaction is complex and involves 
phosphorylation at two sites on the enzyme. The 
rapid phosphorylation of one serine on the P-subunit 
of phosphorylase kinase converts it to a form which 
is 40-times more active. The subsequent, slower, 
phosphorylation of a further serine on the a-subunit 
greatly enhances the rate at which the P-subunit can 
be dephosphorylated and therefore determines the 
time at which the inactivation of phosphorylase 
kinase can be initiated [2,3] . 
Cyclic AMP-dependent protein kinase also catalyses 
the phosphorylation of glycogen synthetase resulting in 
its conversion to a less active form, termed glycogen syn- 
thetase bI [4] (fig.1). Glycogen synthetase is however 
also phosphorylated by glycogen synthetase kinase-2, 
which converts it to another less active, but kineti- 
cally distinct, form termed glycogen synthetase bz [4] 
(fig.1). Phosphorylation of glycogen synthetase a by 
both cyclic AMP-dependent protein kinase and glycogen 
synthetase kinase-2 yields an essentially inactive form 
termed glycogen synthetase bI .2 [4] (not illustrated). 
A single enzyme, termed protein phosphatase-III 
has been shown to catalyse the inactivation of phos- 
phorylase, phosphorylase kinase (through the dephos- 
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Fig.1. The regulatory pathway of glycogen metabolism in 
skeletal muscle [ 11. Abbreviations: a, high activity form; b, 
low activity form; Ph, phosphorylase; PhK, phosphorylase 
kinase; CAMP-PrK, cyclic AMP-dependent protein kinase; 
GS, glycogen synthetase; GSKZ, glycogen synthetase kinase-2; 
PrP-II, protein phosphatase-II; PrP-III, protein phosphatase 
III, i, -OH and i, -OP, the dephosphorylated and phosphorylated 
forms of inhibitor-l; i,, inhibitor-2; ki, the heat stable protein 
inhibitor of cyclic AMP-dependent protein kinase. 
phorylation of the P-subunit) and the reactivation of 
both glycogen synthetase bI and bz and therefore 
carriers out all four dephosphorylations which either 
inhibit glycogenolysis or activate glycogen synthesis 
[5,6]. A second activity, termed protein phosphatase- 
II, specifically dephosphorylates the a-subunit of 
phosphorylase kinase, and therefore opposes the action 
of protein phosphatase-III against the P-subunit of 
phosphorylase kinase [S-7] . 
Current interest in the regulation of the protein 
phosphatases of glycogen metabolism was stimulated 
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by the report that liver and muscle extracts contain a 
heat-stable, trypsin-labile protein(s) which is a potent 
inhibitor(s) of phosphorylase phosphatase [8,9]. This 
work was extended by Huang and Glinsmann who 
demonstrated the existence of two heat-stable protein 
inhibitors of phosphorylase phosphatase in skeletal 
muscle extracts, which they termed inhibitor-1 and 
inhibitor-2 [ 10,111. The made the important discovery 
that inhibitor-l only inhibited phosphorylase phospha- 
tase when it was itself phosphorylated by cyclic 
AMP-dependent protein kinase (fig.1). Inhibitor-2 
was effective without the need for prior phosphoryla- 
tion and was distinct from both inhibitor-l and from 
the heat-stable protein which specifically inhibits 
cyclic AMP-dependent protein kinase [ 1 l-l 31. 
We recently showed that a heat-stable protein, 
purified 700-fold from skeletal muscle extracts, and 
which is probably identical to inhibitor-2, inhibited 
all the four activities of protein phosphatase III in 
parallel but it was over 2004imes less effective in 
inhibiting protein phosphatase II [12,13]. 
While the physiological roles of inhibitors-l and 
-2 are not yet known, inhibitor-l could be of con- 
siderable importance in the hormonal control of 
glycogen metabolism. If the phosphorylation of this 
protein occurred in vivo, it might lead to the inactiva- 
tion of protein phosphatase III as cyclic AMP-dependent 
protein kinase became activated, providing a further 
mechanism for amplifying the hormonal activation of 
glycogenolysis and for excercisiirg control over several 
protein kinase-protein phosphatase cycles. Inhibitor-l 
may therefore be a novel protein in metabolic regula- 
tion mediating the control of a protein phosphatase 
by a protein kinase. Knowledge of the structure at the 
phosphorylation site of this protein, given in this 
communication, may therefore provide valuable infor- 
mation about he specificity and mechanism ofaction of 
both interconverting enzymes. 
2. Methods and results 
Inhibitor-l was purified to homogeneity. It showed 
a single protein-staining band when subjected to poly- 
acrylamide gel electrophoresis in the presence of 
sodium dodecyl sulphate, corresponding to mol. wt 
25 000. This is in close agreement to the value report- 
ed by Huang and Glinsmann for the partially purified 
protein [ 1 l] . Phosphorylation of inhibitor-l by 
cyclic AMP-dependent protein kinase resulted in the 
incorporation of one molecule covalently bound phos- 
phate/molecule protein (G. A. Nimmo and P. Cohen 
unpublished results). 
The rate of phosphorylation of inhibitor-l by 
cyclic AMP-dependent protein kinase was compared 
to the rate of phophorylation of two other physiolo- 
gical substrates for this enzyme, phosphorylase kinase 
and histone H-l (fig.2). It was calculated from these 
results that the rate of phosphorylation of inhibitor-l 
was nearly four-times faster than histone H-l and it 
was 30% that of the /I-subunit of phosphorylase kinase. 
32P-Labelled inhibitor-l, 5.0 mg (200 nmol), was 
incubated with 0.5 mg thermolysin in 5.0 ml 0.1 M 
ammonium bicarbonate for 2 h at 37°C. The reaction 
was terminated by lyophilisation and the material 
was then subjected to two-dimensional peptide mappiq 
using pyridine/acetic acid/water, pH 3.6 (1: 10: 190) 
4 
tine (min) 
Fig.2. Relative rate of phosphorylation of inhibitor-l, phos- 
phorylase kinase and histone Hl by cyclic AMP-dependent 
protein kinase. The final concentrations in the assays were, 
protein substrate 6 PM, sodium glycerophosphate 10 mM, 
EDTA 0.4 mM, EGTA 0.1 mM, cyclic AMP 0.01 mM magne- 
sium chloride 2.0 mM and [-r-aZP]ATP 0.2 mM. (o-o) Phos- 
phorylation of phosphorylase kinase by trace endogenous 
cyclic AMP-dependent protein kinase. (e-e) Phosphoryla- 
tion of phosphorylase kinase by endogenous cyclic AMP- 
dependent protein kinaae plus 0.01 units of added partially 
purified cyclic AMP-dependent protein kinase [ 131. (t-v) 
Phosphorylation of inhibitor-l by 0.02 units of cyclic AMP- 
dependent protein kinase. (v-v) Phosphorylation of histone 
Hl by 0.02 units of cyclic AMP-dependent protein kinase. 
The preparations of inhibitor-l and histone Hl did not have 
any endogenous cyclic AMP-dependent protein kinase activity. 
183 
Volume 76, number 2 FEBS LETTERS April 1977 
Table 1 
Amino acid composition of the phosphopeptide obtained 
by digestion of “P-1abelled inhibitor-l with thermolysin 
Amino acid 
Threonine 
Glutamic acid 
Proline 
Glycine 
Alanine 
Isoleucine 
Lysine 
Arginine 
“P-Radioactivity 
Total 
1.75 (2) 
0.17 
2.10 (2) 
0.16 
1.09 (1) 
1.00 (1) 
0.14 
3.94 (4) 
0.92 (1) 
10 
Impurities below 0.1 residues are omitted. 
for 75 min at 50 V/cm. Descending chromatography 
was carried out in the second-dimension using butanol/ 
pyridine/acetic acid/water (90:60: 18:72) for 40 h. 
The paper was autoradiographed and showed the 
presence of one major 32P-labelled peptide which con- 
tained > 95% of the 32P-radioactivity on the paper 
(not illustrated). This peptide had an electrophoretic 
migration of 0.6 relative to lysine, and a chromato- 
graphic mobility of 0.1 relative to phenol red. The 
32P-labelled peptide corresponded in position to a 
strongly staining fluorescamine positive spot. The 
peptide was eluted using 1 .O M acetic acid and 60 nmol 
peptide was obtained corresponding to an overall 
yield of 30%. 
An aliquot of the purified peptide was hydrolysed 
in 6 N HCl and subjected to amino acid analysis. The 
amino acid composition (table 1) indicated that ,the 
peptide contained ten amino acids, four of which were 
arginine. The amino acid composition also surprisingly 
indicated that serine was absent from the peptide. In 
order to establish that the protein was phosphorylated 
on a threonine residue, an aliquot of the 32P-labelled 
protein was subjected to partial acid hydrolysis, follow- 
ed by electrophoresis at pH 1.9. The results confirmed 
that inhibitor-l was phosphorylated on a threonine 
residue (fig.3). In contrast, 32P-labelled phosphorylase 
kinase hydrolysed under similar conditions showed 
only the presence of phosphoserine and not phospho- 
threonine (fig.3), as expected from the known struc- 
ture of the two phosphorylation sites on the enzyme 
131. 
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Fig.3. Identification of phosphothreonine in inhibitor-l. 
3zP-Labelled phosphorylase kinase (A) and inhibitor-l (B), 
prepared by maximal phosphorylation with cyclic AMP-1 
dependent protein kinase, were hydrolysed with 6 N EC1 at 
110°C for 1.5 h and 4.0 h, respectively. The samples were 
dried and subjected to electrophoresis in acetic acid/formic 
acid/water (2: 1: 25) pH 1.9, at 50 V/cm for 1 h. The figure 
shows an autoradiograph of the electrophoretogram. The 
radioactive spots near the origin represent incompletely 
hydrolysed material. 
The complete amino acid sequence of the peptide 
was established unambiguously by the micro dansyl- 
Edman procedure of Bruton and Hartley [ 141 and was 
entirely consistent with the amino acid composition 
(table 1). The amino acid sequence was shown to be: 
Ile-Arg-Arg-Arg-3-PrT-Th$P)-Pz-Ala--T% 
---- 
- 
The identity of phosphothreonine as the seventh resi- 
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due was established by the simultaneous appearance 
of two dansyl derivatives, dansyl phosphothreonine, 
which migrates at a characteristic position below 
serine in the third solvent (ethyl acetate/methanol/ 
acetic acid, 20: 1: 1) and dansyl threonine resulting 
from partial hydrolysis of the phosphorylated amino 
acid derivative. The C-terminal threonine residue was 
confirmed by digestion with carboxypeptidase A. 
3. Discussion 
The results presented in this paper show that cyclic 
AMP-dependent protein kinase phosphorylates just 
one site on inhibitor-l. The structure at the phosphory- 
lation site is also very unusual since firstly it includes 
a sequence of four consecutive arginines and secondly 
the phosphorylation occurs on threonine and not on a 
serine residue. 
A sequence of four arginines has, to our knowledge, 
only been observed in one other class of protein, 
namely the protamines which are complexed with 
nucleic acids in the mature sperm of some fish and 
birds. These proteins contain about 32 amino acids 
of which 70% are arginine residues, and they contain 
several sequences of four or five consecutive arginine 
residues [ 151. The homology with protamines actually 
extends beyond this, since the pentapeptide arg-arg- 
arg-arg-pro occurs in all protamines, while the hexa- 
peptide ile-arg-arg-arg-arg-pro is found in two 
protamines [ 151. Even though the probability of 
obtaining two identical hexapeptide sequences by 
chance is exceedingly low, it is difficult to believe that 
inhibitor-l and protamines are derived from a common 
ancestral protein, since inhibitor-l contains 200 amino 
acids, it is not a basic protein and it contains only 
15 arginine residues in the whole molecule (G. A. 
Nimmo and P. Cohen unpublished results). Neverthe- 
less, it is intriguing that protamine is a potent inhibitor 
of phosphorylase phosphatase activity (A. Burchell 
and P. Cohen unpublished results). In the standard 
assay [6] , the Ki was l-2 PM, and even allowing for 
the presence of 20 arginines/molecule of protamine, 
this is at least 10004imes more inhibitory than equi- 
valent amounts of free arginine (Ki = 5 X lo-’ M), 
which has been known for 20 years to inhibit phos- 
phorylase phosphatase [161, The phosphorylated 
form of inhibitor protein-l is however a much stronger 
inhibitor of protein phosphatase III than protamines. 
The amino acid sequence at the sites on phosphory- 
lase kinase, histones Hl and H2B and pyruvate kinase 
which are phosphorylated by cyclic AMP dependent 
protein kinase are given in table 2. These proteins 
represent he best substrates for cyclic AMP-dependent 
Table 2 
Amino acid sequences at the phosphorylation sites of substrates for cyclic AMP-dependent protein kinase 
Substrate Sequence Reference 
Phosphorylase kinase 
(p-subunit) 
Histone H2B 
Pyruvate kinase 
(rat liver) 
Inhibitor-l 
Phosphorylase kinase 
(a-subunit) 
Histone Hl 
(rat liver) 
loo Val Ala-Arg-Thr-Lys-Arg-Ser-Gly-Ser(P)-Ile -Tyr-Glu-Pro-Leu-Lys - -- [17,181 
Lys-Lys-Arg-Lys-Arg-~r(P)-Arg-Lys-Glu-~~(P)-Tyr-Ser-Val-Tyr-Val-Tyr-Lys [ 17,181 ----- -- -_- 
35 
Gly-Val-Leu-Arg-Arg-Ala-Ser(P)-Val-Ala-Glx-Leu [18,19] -- --- 
30 
Be -Arg-Arg-Arg-Arg-Pro-Thr(P)-Pro-Ala-Thr This paper ---- --- 
20 
Phe-Arg-Arg-Leu-Ser(P)-Ile -Ser-Thr-Glu-Ser-Glx-Pro 117,181 -- --- 
8 
Ala-Lys-Arg-Lys-Ala-Ser(P)-Gly-Pro-Pro-Val-Ser --- --- WI 
The numbers above the phosphorylated residues refer to the rates at which the sites are phosphorylated relative to the psubunit 
of phosphorylase kinase (100%). The assay conditions are given in fig.2. Basic amino acids are underlined and broken lines indicate 
the phosphorylated residue. 
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protein kinase in vitro that have been identified. We 
have pointed out previously that a striking feature 
common to each of these sequences is the presence of 
two adjaeent basic amino acids, at least one of which 
is arginine, just N-terminal to the phosphorylatable 
residue [17,18] and in this respect the structure of 
the phosphorylation site of inhibitor-l can be said to 
conform to the basic specificity pattern that seems to 
be emerging. 
The importance of two adjacent basic amino acids 
has been emphasized by the resultsof Zetterqvist 
et al. [21] and Kemp et al. [22] who have studied 
the phosphorylation of synthetic peptides correspond- 
ing to the phosphorylation site of pyruvate kinase 
(table 2). Zetterqvist et al. [21] found that the hepta- 
peptide leu-arg-arg-ala-ser-val-ala- was phos- 
phorylated with kinetic constants (Km and V,,) 
comparable to those of the native protein. Further- 
more, if either arginme of the pentapeptide arg-arg- 
ala-ser-val- was replaced by a leucine, the rate of 
phosphorylation of the peptide fell by more than 
loo-fold. However, they also reported that if the 
serine in the pentapeptide was replaced by a threonine, 
then the rate of phosphorylation of the peptide again 
fell by more than loo-fold. This suggested that the 
presence of threonine might not be compatible with 
rates of phosphorylation required in vivo, and was 
consistent with the finding that all physiological sub- 
strates to date were phosphorylated on serine residues 
(table 2). However, the present finding, that inhibitor 
protein-l is phosphorylated on a threonine residue 
at a similar rate to other physiological substrates 
(table 2, figure 2) shows the molecular specificity of 
cyclic AMP-dependent protein kinase must be more 
complex and suggests the need to carry out more 
extensive specificity studies with synthetic peptides. 
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